Indoco Remedies Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y04fni0eghkum6bni1nzmr54.pdf

Key Takeaways


US Business: Delays, Profit Shares & the FDA Overhang

Aditi Panandikar: "...we bent backwards on account of that both Teva and us have been exceedingly over careful in supplying product to the US market. That has resulted in a delay in supply of a particular strength and that is why when you look at Brinzolamide, you look at the whole market, when we say the supply and sale has started, it is actually in the smaller market. So, the real returns are yet to come from both sale as well as margin."

Margin Walk: MTM, Mix & the Procurement Promise

Aditi Panandikar: "Indoco today would prefer to keep the IP for ourselves. So, this is the kind of an intended kind of a shrinkage of service income which as you know is much higher margins in the commercial space, but over a period of time we will get much better returns from this portfolio."

India Business: Steady Growth with a Shifting Mix


Europe: Steady Growth, Tender Wins & Manufacturing Shifts


Capacity, CAPEX & the Path to ₹5,000 Crores

Aditi Panandikar: "Safe to say that we will ensure that even if India business does not contribute 50% of topline, the other business contributing largely to the topline which will be US, we will deliver on similar margins as India or more."

Quality & Regulatory: Observations as "Part of Business"

Aditi Panandikar: "I think it is best on such calls to not give any assurance that we will come out clear or not... the number of SAR we file, the number of recall you do, all of that is an expression of a good quality management system. So, I feel confident that we are better able to manage quality than before, all the same when the auditors walk in. If there are any improvement issues, I am sure we will have observations. We should not be afraid of it."

Guidance & Commitments

CommitmentSpecificsTimeline
US revenue₹280–285 Cr in FY23 despite two product approval delaysFY23
Brinzolamide profit shareLikely to fall in Q4 FY23, but management noted a delay and expects profit shares to come in as and when sales happenQ4 FY23
Procurement cost benefitsMaterial effect to be seen largely from Q4 FY23 onwardsQ4 FY23 onwards
Europe growth20% growth, described as a "done thing"Next year (FY24)
India revenueClose to ₹830 Cr for FY23; Q4 at ~₹217 CrFY23
CAPEXClose to ₹300 Cr to support increased US shareMedium term (to ₹5,000 Cr topline)
ROCEImprove from ~13% to 15%By the time topline reaches ₹5,000 Cr
Topline aspiration₹5,000 CrFY27–28
Allopurinol Germany tenderSupplies at ~₹65–70 Cr per year for the next 2 yearsNew 2-year contract

Key Metrics

MetricQ3 FY23
Net revenue₹410.6 cr, +17.8% YoY vs ₹348.6 cr
Net revenue (9M FY23)₹1,210.10 cr, +9.8% YoY vs ₹1,102.4 cr
EBITDA to net sales15.0% at ₹61.7 cr vs 21.1% at ₹73.4 cr YoY
EBITDA without other operating income17.9% at ₹73.6 cr vs 18.4% at ₹64.3 cr YoY
PAT to net sales6.8% at ₹27.9 cr vs 9.5% at ₹33 cr YoY
Earnings per share₹3.03 vs ₹3.58 YoY
Domestic formulation revenue₹203.6 cr, +12.2% YoY vs ₹181.5 cr
International formulation revenue₹186.10 cr, +30.10% YoY vs ₹143 cr
US business revenue₹60.3 cr, +22.8% YoY vs ₹49.10 cr
Europe revenue₹86 cr, +58.5% YoY vs ₹54 cr
Regulated markets revenue₹151.7 cr, +39.5% YoY vs ₹108.7 cr
Emerging markets revenue₹34.4 cr, flat YoY
API business revenue₹16.2 cr vs ₹19.7 cr YoY
IPM rank and market share28th, market share of 0.67%
India business net price growth5–6%
US FY23 revenue guidance₹280–285 cr, revised from ~₹300 cr earlier
ROCE13% as on 31/12 vs 15% same time last year
Exchange fluctuation impact (net loss)₹14.03 cr in Q3, MTM and realized/unrealized
Allopurinol Germany tender annual value₹65–70 cr per year for next 2 years, 90.5% market share won
Pending US ANDA approvals~25 products across all sites, 10 own ANDAs
CRO capacity~150 beds after adding 48 beds to earlier ~98